Pfizer shares jump over 10% on strong Q3 profit and margin expansion

Pfizer Ltd shares surged over 10% on Tuesday, February 10, after the company delivered a strong set of Q3FY26 results, driven by healthy revenue growth and sustained margin expansion.

The stock gained 10.35% to hit intraday highs of ₹5,257, continuing its gaining streak from Monday, when it closed 3.79% higher at ₹4,764.10 apiece.

For the December quarter, Pfizer reported revenue of ₹645.03 crore, up 20%

year-on-year from ₹537.99 crore, supported by steady demand across key brands. Operating margins improved sharply to 35.4% from 27.1% a year ago, reflecting improved operating leverage and a favourable product mix.

Net profit for the quarter rose 13% year-on-year to ₹143.71 crore, compared with ₹127.6 crore in Q3FY25, while sequentially, profit jumped sharply on the back of stronger margins.

For the nine months ended December FY26, revenue grew 11.9% to ₹1,890.42 crore, while net profit increased 19.7% year-on-year to ₹522.61 crore. Margins for the nine months also expanded to 35.3% from 30.3% in the year-ago period.

Also read: RailTel shares jump nearly 8% after bagging ₹4,550 crore West Central Railway order

Management commentary highlighted that margins have been maintained at around 35%, with growth expected to be driven by marquee brands, including Prevenar 13, Eliquis, Zavicefta, Meronem, and Minipress, alongside established products like Corex-DX, Gelusil, and Folvite.

Pfizer is the fourth-largest multinational pharmaceutical company in India, with a portfolio of over 150 products across 16 therapeutic categories. The company continues to maintain a strong balance sheet, having generated ₹816 crore in operating cash flows in FY25 and holding cash and cash equivalents of ₹2,801 crore.

While the stock hit an intraday high of ₹5,257 earlier on Tuesday, it has since pared some of its gains and is trading 8.27% up at ₹5,158 as of 11.04 am.